Letter to the Editor
W e feel th at Alex ander S. Young's recent a r ticle, " T he neurolept ic t rea tm e nt of schizophre nia: do sing strat egi es, d epot pr eparations and novel m edi cation s" ijournal, 13, 18-26), may overs tat e t he r isks a nd com plica tions associat ed with t he use of c1 ozapin e. While pre-marketing data (a s cite d in the pa cka ge in sert) I did sugges t th at cloza pine had a relative ly hi gh incid en ce of se rious adve rse e ffect s, post-marketing su rve illa nce by the C loza ri l Pa t ie n t Monit oring Se rvice (C PMS) does not co nfirm this. It would be un for tunat e if you r readers were left with th e impression that th e usc of cloza pine were mor e di fficult or da ngerous than it trul y is.
Young d escribes th e risk of ag ra nu locytos is a s 1%, with a d eath rat e o f 0.05%. Ba sed on data collec te d by the C PMS on 99,502 patients to th e e nd of 1994, a more up-to-da te figure would be 0.38%, with a tot al of 12 ag ra n ulocytos is-rel a te d d eaths (o r 0.01%) in th e United Sta tes "; this com pa res favor ably to th e ag ra n ulocytosis rat es of up to 0.7% which have been obse rve d with ph en ot hi a zin es'' a nd, give n t he required wee kly hematolog ical monitoring, may well res ult in a lowerd eath rat e fr om blood d yscrasia s t ha n is see n with typ ica l neuroleptics.
The risk of c1ozapine -associa te d se izu res a lso a ppears now to be sig nifica n tly less than sugges te d by th e St age III s t ud ies. Again, post-m arketing su rve illa nce via th e C PMS sugg ests a se izu re rate of 1.3% in the U n ite d Stat es;" of th ese patients, half were co nc u r re n tly receivin g m edi cations known to lowe r th e se izu re threshold and a third had a pri or hi st or y of se izures. Only 0.4% of patients had recurrent se izures-t he o t he rs were isolat ed sing le event s during initia l d ose titration-and thre e-quart ers of th ose pat ients we re a ble to co n tinu e ta king clozapine with the a dd itio n of a n a n ti-co nv ulsa nt. In ad d it ion, seizure rates appear to be co ns ide ra bly lower in Europ e, with o nly o ne se izu re rep ort ed in 765 patients t reated by th e Munich g ro u p,' ·6 a nd sim ila r data from ot he r ce n te rsr /-" this m ay refl ect th e lowe r (but see m ingly eq ually efficac ious) do sages of cloza pine used th ere.
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These figures again co mpare favorab ly wi th t he 0.5-1% incid e nce of se izu res as socia te d wit h typi cal neurol cpt ics. !" Whi le we agree th at respirat ory a r res t is a n ex t re m ely rare, but recognize d, adve rs e e ffect a ssociat ed with cloza pine us c, we would di sagree wit h the recom m endation th a t " pa t ien ts sho uld not be on ben zodi az epines wh en starti ng cloza pine ." It is ce rtai nly tru e that this co m bina t ion ca n ca use ex t re me se da t ion (to th e point of ob tu nda tion), pa rt icularly in t he ea rl y s tages of cloza pine dose titration. II H oweve r, of th e six reported cases of respira tory arrest a ssoc ia te d wit h t he com bina t io n, four pa t ie n ts were on extre me ly high doses of or al ben zodi aze pines (up to 32 m g/d a y lo ra zepa m eq uiva le n ts ) a nd were started on conside ra bly high e r doses of cloza pine th an re comme nd ed by th e m a n ufact urer. F whi le th e other cases l3 . 14 rep or ted pat ients on lon g-sta nd ing clozapine t herapy wh o were ad m inis tered intraoenous be nzod iazepines, a rout e whi ch is we ll-r ecognized as producin g a n id iosyncr atic, non-dose-depe nd e n t respiratory a r re st in susce p tible pe rsons.I> Alt ho ug h th e manufacturer's dat a she et I urges ca u tion in the conco m ita n t pr escr ip ti on of cloza pine and be nzo d ia zepines, thi s regim en is no t con t ra-ind ica te d .
T he use of cloza pine does requ ire spe cia l p reca ution s a nd incr e a sed vigilance, but it would be unfortunat e if pat ients suffe ring fro m a painful, terrifyin g a nd d evastati ng di sea se were 4 1
